参灵固本丸在乳腺癌辅助化疗中预防蒽环类药物心脏毒性的临床作用探析  

Preventive Effect of Shenling Guben Pills on the Cardiotoxicity of Anthracycline Drugs in Adjuvant Chemotherapy of Breast Neoplasms

作　　者：李秋华[1] 王宁[1] 潘淑云[1] 韩晓晴[2] 谢晓冬[3] 刘兆喆[3] LI Qiuhua;WANG Ning;PAN Shuyun;HAN Xiaoqing;XIE Xiaodong;LIU Zhaozhe(The Second Affiliated Hospital of Liaoning University of Chinese Medicine, Shenyang l10034;Liaoning University of Chinese Medicine, Shenyang 110847;Department of Oncology, General Hospital of Shenyang Military Area Command, Shenyang 110016)

机构地区：[1]辽宁中医药大学附属第二医院,辽宁沈阳110034 [2]辽宁中医药大学,辽宁沈阳110847 [3]沈阳军区总医院,辽宁沈阳110016

出　　处：《湖北中医药大学学报》2017年第6期21-25,共5页Journal of Hubei University of Chinese Medicine

基　　金：科技部十二五重大新药创制平台子课题(项目编号:2012ZX-09303016-002);辽宁省科技攻关计划课题(项目编号:2012225019);辽宁省中医药临床专(学)科能力建设项目(项目编号:2014-01)

摘　　要：目的观察参灵固本丸配合乳腺癌辅助化疗对于改善蒽环类药物导致的心脏毒性临床效果研究。方法 78例收治的住院患者随机分成两组,对照组应用CEF方案化疗,治疗组患者化疗同时配合参灵固本丸5g,3次/日口服。共6周期治疗,每间隔2周期分别观察两组患者的临床疗效、中医症状评分、生活质量、超声心动图、心电图,血清肌钙蛋白(cTnT)及血清肌酸激酶(CK)含量。结果第4、6周期后,治疗组症状评分下降明显,对照组评分增高,两组均与治疗前相比差异显著(P<0.05),且组间差异显著(P<0.05)。第4、6周期后,治疗组卡氏功能状态评分(KPS)与治疗前比较下降,差导显著(P<0.05)。第2、4、6周期后,对照组KPS评分下降,与治疗前比较,差异明显(P<0.05),两组组间比较差异明显(P<0.05)。治疗第4、6周期后,治疗组血清肌钙蛋白(cTnT)、对照组血清肌钙蛋白(cTnT)均较治疗前明显增高(P<0.05),第6周期后,cTnT值组间差异明显(P<0.05)。治疗后,两组CK含量,较治疗前增高(P<0.05),且组间差异明显(P<0.05)。伴随化疗进程,两组左室射血分数降低,化疗第4、6个周期,两组左室射血分数值与治疗前相比差异显著(P<0.05),且组间差异明显(P<0.05)。结论参灵固本丸可预防蒽环类药物的心脏毒性,改善患者生存质量。Objective To observe the preventive effect of Shenling Guben pills on the cardiotoxicity of anthracycline drugs in adjuvant chemotherapy of breast neoplasms. Methods 70 cases of hospitalized patients were randomly divided into control group and treatment group, control group received CEF （ cyclophosphamide ＋ epirubicin ＋ fluorouracil ） chemotherapy, treatment group received Shenling Guben pills on the basis of control group, 5g each time, 3 times a day oral, 21d was a chemo- therapy treatment eyele, totally treated for 6 cycles.TCM symptom scores, the quality of life, the echocardiography, serum creatinine calcineurin （cTnT）, creatine kinase （CK） content changes were observed at intervals of 2 cycles. Results The symptom grade of treatment group decreased significantly, while control group increased, compared with before treatment, there were significantly difference （P〈0.05）, and the differences between the two groups were significantly different （P〈0.05）. The KPS grade of treatment group reduced at the end of the 2nd, 4th, 6th cycles, compared with before treatment, the reduction was significantly different （P〈0.05）, and the differences between the two groups were significant different （P〈0.05）. The cTnT of both groups at the end of the 4th, 6th cycles was significantly higher than that before treatment （P〈0.05）, and there were significant differences between the two groups in the 6th cycle （P〈0.05）. After treatment, the serum creatine kinase （CK） content was higher in treatment than before treatment, the difference was significant （P〈0.05）. With the process of chemotherapy, left ventricular ejection fraction in both groups reduced, there was significantly difference from that before treatment （P〈0.05）, and the difference between the two groups was significant （P〈0.05）.Conclusion Shenling Guben pills can prevent anthracycline cardiotoxicity, reduce chemotherapy side effects and enhance the quality of life of patients.

关 键 词：乳腺癌 参灵固本丸 蒽环类药物 化疗 心脏 药物毒性 

分 类 号：R285.5[医药卫生—中药学]